Medicine Recommendations

Neuropathic pain

To relieve and/or prevent withdrawal symptoms and reduce the cravings associated with tobacco dependence

Please note: eVoke and Voke are different products. For Voke see separate entry

Adjunct to co-beneldopa or co-careldopa in Parkinson's disease

Preventing migraine (NICE TA871)

NICE TA 971 - Eptinezumab for preventing migraine

For preventing migraine (NICE TA682)

Generalised anxiety disorder

MHRA Drug Safety Update - Citalopram and escitalopram: QT interval prolongation

*FOR FYLDE & WYRE CCG ONLY* - Consultant initiated, only after Sertraline tried.

Major Depressive illness

MHRA Drug Safety Update - Citalopram and escitalopram: QT interval prolongation

Treatment of resistant depression (NICE TA854)

NICE TA854 - Esketamine nasal spray for treatment-resistant depression

Adjunctive therapy in patients with partial-onset seizures with or without secondary generalisation

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Epilepsy

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Pain

MHRA Drug Safety Update - Serious and fatal overdose of fentanyl patches

MHRA advice: Fentanyl skin patches: How to use and dispose of them safely

Pain (as per LSCMMG Position Statement)

MHRA Drug Safety Update - Serious and fatal overdose of fentanyl patches

MHRA advice: Fentanyl skin patches: How to use and dispose of them safely

Non cancer pain

Depressive illness, Bulimia Nervosa, Obsessive Compulsive Disorder

MHRA Drug Safety Update  - Fluoxetine: possible small risk of congenital cardiac defects

Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of schizophrenia and psychoses

Maintenance in schizophrenia and other psychoses

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Depressive illness, obsessive compulsive disorder

The colour classification was determined as part of the collaborative work between LCFT and medicines management leads. Local pathways and patient safety were taken into consideration.